Casdatifan

Casdatifan
Clinical data
Other namesAB-521
Identifiers
  • (5R,6S,8R)-3,5,6-Trifluoro-8-[(1S,2R)-2-fluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC21H17F4NO3S
Molar mass439.42 g·mol−1
3D model (JSmol)
  • CS(=O)(=O)C1=C2[C@@H]([C@@H](CC2=C(C=C1)[C@H]3C[C@@H]([C@@H](C4=CC(=CC(=C34)C#N)F)F)F)F)O
  • InChI=1S/C21H17F4NO3S/c1-30(28,29)17-3-2-11(13-7-16(24)21(27)19(13)17)12-6-15(23)20(25)14-5-10(22)4-9(8-26)18(12)14/h2-5,12,15-16,20-21,27H,6-7H2,1H3/t12-,15+,16-,20-,21-/m1/s1
  • Key:KHBHHNNBNHHGPE-QCCZFBHPSA-N

Casdatifan is an investigational new drug that is being evaluated by Arcus Biosciences and AstraZeneca for the treatment of renal cell carcinoma. It is an inhibitor of endothelial PAS domain-containing protein 1 (HIF‑2α).

Pharmacology

Casdatifan is allosteric HIF‑2α inhibitor with low-nanomolar potency in cell-based reporter assays.

Clinical trials

Casdatifan in combination with cabozantinib (a tyrosine-kinase inhibitor) is currently in phase 3 clinical trials for the treatment of advanced clear cell renal cell carcinoma.